Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Works matching IS 11707690 AND DT 2021 AND VI 39 AND IP 2
Results: 9
1
2
NICE's Discounting Review: Clear Thinking on Rational Revision Meets Obstacle of Industrial Interests.
- Published in:
- PharmacoEconomics, 2021, v. 39, n. 2, p. 139, doi. 10.1007/s40273-020-00990-8
- By:
- Publication type:
- Article
3
Modifying NICE's Approach to Equity Weighting.
- Published in:
- PharmacoEconomics, 2021, v. 39, n. 2, p. 147, doi. 10.1007/s40273-020-00988-2
- By:
- Publication type:
- Article
4
Health State Utilities of Patients with Heart Failure: A Systematic Literature Review.
- Published in:
- 2021
- By:
- Publication type:
- research
5
Comparing the Analysis and Results of a Modified Social Accounting Matrix Framework with Conventional Methods of Reporting Indirect Non-Medical Costs.
- Published in:
- PharmacoEconomics, 2021, v. 39, n. 2, p. 257, doi. 10.1007/s40273-020-00978-4
- By:
- Publication type:
- Article
6
The Budget Impact of Including Rucaparib on a US Payer Formulary for the Treatment of Patients with Metastatic Ovarian Cancer.
- Published in:
- 2021
- By:
- Publication type:
- journal article
7
Dealing with Bad Risk in Cost-Effectiveness Analysis: The Cost-Effectiveness Risk-Aversion Curve.
- Published in:
- 2021
- By:
- Publication type:
- journal article
8
An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis.
- Published in:
- PharmacoEconomics, 2021, v. 39, n. 2, p. 181, doi. 10.1007/s40273-020-00965-9
- By:
- Publication type:
- Article
9
Predictors of Health Utility in Relapsing–Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies.
- Published in:
- PharmacoEconomics, 2021, v. 39, n. 2, p. 243, doi. 10.1007/s40273-020-00964-w
- By:
- Publication type:
- Article